Dina Ramadan's questions to Travere Therapeutics Inc (TVTX) leadership • Q3 2024
Question
Dina Ramadan from Bank of America asked about the broader market opportunity for FILSPARI in FSGS, including whether it requires market building and the potential challenges for a new therapy in a space with no approved treatments.
Answer
Chief Commercial Officer Peter Heerma estimated the addressable U.S. market at 15,000 to 30,000 patients, noting it's the same prescriber base as IgAN, which should lead to rapid uptake. Chief Medical Officer Dr. Jula Inrig added that there is a high unmet need for effective, non-immunosuppressive therapies. President and CEO Dr. Eric Dube concluded that they expect to become the leader and new standard of care.